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A B S T R A C T
Female genital schistosomiasis (FGS) results from egg-deposition in the female reproductive tract primarily by
the waterborne parasite Schistosoma (S.) haematobium, and less commonly by Schistosoma (S.) mansoni. FGS
affects an estimated 20-56 million women worldwide, mostly in sub-Saharan Africa. There is cross-sectional
evidence of increased HIV-1 prevalence in schistosomiasis-infected women, but a causal relationship between
FGS and either HIV-1 acquisition or transmission has not been fully established. Beyond the pathognomonic
breach in the cervicovaginal barrier caused by FGS, this narrative review explores potential mechanisms for a
synergistic relationship between S. haematobium infection, FGS, and HIV-1 acquisition through vaginal in-
flammation and target cell recruitment.
1. Introduction
There are an estimated 82 million African women living with
Schistosoma infections (Lai et al., 2015). Though the risk factors for
human immunodeficiency virus-1 (HIV-1) and Schistosoma haematobium
are different, these two conditions share a substantial geographic
overlap (Figure 1A and 1B). Worldwide, 53% of people living with HIV-
1 reside in Eastern and Southern Africa, where the HIV-1 epidemic
disproportionately affects young women (UNAIDS 2018). In 2017, 52%
of the 36.9 million people living with HIV-1 were women aged 15 years
and over (UNAIDS 2018). The synergy of many co-factors present in
Africa increases the risk of heterosexual HIV-1 acquisition, namely high
prevalence of bacterial vaginosis and sexually transmitted infection
(STI) (Cohen et al., 2012), low uptake of circumcision in adult men
(Kaul et al., 2015), baseline immune activation, and endemic co-in-
fections (Modjarrad, 2010). In addition, schistosome infection in
women (Downs et al., 2012), and more specifically, female genital
schistosomiasis (FGS), has been associated with prevalent HIV-1 in-
fection (Kjetland et al., 2006; Downs et al., 2011).
This review will focus on FGS and its causative agent, the parasite S.
haematobium, which requires an aquatic environment and a freshwater
snail vector to complete its life-cycle (Colley et al., 2014). When ferti-
lized S. haematobium eggs are shed in human urine and enter fresh
water, the miracidia hatch and penetrate a snail host. After 4-6 weeks,
cercariae penetrate human skin and enter the bloodstream
(Colley et al., 2014). S. haematobium eggs are often laid in the vesicular
plexus where proximity to the pelvis’ venous drainage provides circu-
lating eggs access to male and female urogenital tissues. FGS occurs
when circulating S. haematobium eggs lodge in the reproductive organs.
FGS has been associated with poor reproductive health outcomes in-
cluding ectopic pregnancy (Helling-Giese et al., 1996), abortion
(Helling-Giese et al., 1996), and infertility (Kjetland et al., 2010), likely
as a consequence of parasite egg deposition and inflammation in re-
productive tissues. It is hypothesized that the relationship between FGS
and HIV-1 acquisition is causal, with the mucosal breach caused by FGS
allowing HIV-1 access to susceptible submucosal target cells. However,
there have been no longitudinal studies investigating the mechanistic
links between FGS and HIV-1 acquisition. This review explores poten-
tial mechanisms for the relationship between S. haematobium, FGS, and
HIV-1 acquisition beyond a breach in cervicovaginal mucosal barrier
function.
2. Methods
2.1. Search Criteria
References for this narrative review were identified through
searching PubMed and Medline databases up to February 4, 2020 with
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the use of terms “Schistosomiasis” OR “Schistosoma” OR “Female
Urogenital Schistosomiasis” OR “Genital or Urogenital Schistosomiasis”
OR “Genital or Cervicovaginal Inflammation”, AND “HIV or Human
Immunodeficiency Virus”. The references of relevant articles were also
used to identify additional sources. No language restrictions were ap-
plied.
2.2. Selection Criteria
To be eligible for this narrative review (Gasparyan et al., 2011),
studies must have included some proportion of women who had a de-
finitive diagnosis of FGS, including either detection of Schistosoma (S.)
DNA by molecular methods or through histopathologic diagnosis (eggs
of either S. haematobium or S. mansoni detected in genital tissue). Stu-
dies were also eligible for inclusion if they contained a comparator
group for both prevalent HIV-1 and FGS and were prospective
(randomized or non-randomized) or cross-sectional studies in African
populations. Initially, we searched for studies that evaluated the asso-
ciation between prevalent HIV-1 and FGS, but only identified two stu-
dies that fit these criteria (Supplementary Table 1). We therefore added
an additional question regarding the association of non-genital schisto-
somiasis with prevalent HIV-1 in African populations, with analogous
inclusion criteria to the first study question; however, with the re-
quirement that some proportion of the study population have a measure
of active schistosome infection (defined by positive microscopy or
parasite circulating anodic antigen (CAA) or circulating cathodic an-
tigen. We identified ten studies with relevant information on this
question (Supplementary Table 2).
Beyond the study questions discussed above, where studies focusing
on FGS were not identified, we include findings from publications re-
porting S. haematobium infection or urogenital schistosomiasis as a
narrative synthesis. In circumstances where S. haematobium data were
Figure 1. Overlapping geographical distributions of schistosomiasis infection, HIV-1 prevalence, reported cases of FGS, and infertility. (A) Prevalence of S. hae-
matobium infection in school-aged children in Sub-Saharan Africa from 2000 onwards (from (Lai et al., 2015)); (B) HIV prevalence in African adults (15-49) (from
(UNAIDS 2018)); (C) African countries with published reports of FGS (adapted from (Christinet et al., 2016)), FGS cases have been published by countries shaded in
red; (D) Secondary infertility in Sub-Saharan Africa (from (Larsen 2000)).
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not available, we reference literature relating to S. mansoni.
2.3. Data Extraction & Synthesis
One reviewer identified the eligible articles (A.S.) and two re-
viewers (A.S. and E.W.) extracted relevant data. We extracted study
location, study design, participant ages, the author's definition of FGS,
proportions of study participants with FGS/schistosome infection,
proportion of study participants with HIV-1, method of Schistosoma egg
detection, and the association between FGS/schistosome infection and
HIV-1. Studies relating to our primary question of the association of
FGS with HIV-1 are shown in Supplementary Table 1. Studies relating
to the association of non-genital schistosome infection with HIV-1 are
shown in Supplementary Table 2. Other articles identified in the search
are referenced herein.
3. Female Genital Schistosomiasis – Definition, Clinical
Presentation & Impact
3.1. Urinary schistosomiasis, genital schistosomiasis and their overlap
A working group from the World Health Organization coined the
term “urogenital schistosomiasis” in 2009 to describe the frequent co-
existence of S. haematobium ova in the urinary tract (urinary schisto-
somiasis) and the female genital tract (genital schistosomiasis)
(World Health Organization 2009). Female Genital Schistosomiasis
(FGS) refers therefore, to the presence of S. haematobium eggs, DNA, or
characteristic clinical changes specifically in the genital tract (Figure 2),
regardless of whether or not these are present in the urinary tract
(Kjetland et al., 1996; Kjetland et al., 2005). Female Urogenital Schis-
tosomiasis (FUS) refers more broadly to the deposition of schistosome
eggs in either the female urinary or genital tracts, or both. FGS is caused
most frequently by the parasite S. haematobium. S. mansoni eggs have,
albeit rarely, also been found in genital tissue (Downs et al., 2011).
3.2. The burden of Female Genital Schistosomiasis
With up to 163 million Africans infected with S. haematobium or S.
mansoni (Lai et al., 2015), schistosomiasis morbidity is an under-
estimated public health problem in many parts of sub-Saharan Africa
(World Health Organization 2017). In the 2017 Global Burden of Dis-
ease Study, schistosomiasis was estimated to cause the loss of 1,440
million disability-adjusted life years (DALYs) (Global Burden of Disease
DALYs and Hale Collaborators 2018). Many women acquired S. hae-
matobium infection in childhood, and 30 to 75% of infected women may
develop FGS (Leutscher et al., 1998; Kjetland et al., 2005). A study in
Tanzania reported that 43% (53/122) of women with urinary schisto-
somiasis had concurrent FGS (diagnosed by cervical biopsy)
(Poggensee et al., 1998). A cross-sectional study of girls aged 10-12 in
KwaZulu-Natal, South Africa reported that significantly more girls with
urinary S. haematobium infection reported gynecologic symptoms
(bloody or foul-smelling vaginal discharge) and genital discomfort
(prior to sexual debut and menstruation in 98.6% and 93.0%, respec-
tively) (Hegertun et al., 2013). To our knowledge no clinical studies
have evaluated cervicovaginal physical exam findings in school-aged
girls. However, this study suggested that girls with urinary S. haema-
tobium infection may develop the genital changes associated with FGS
prior to sexual debut or the onset of menstruation. Since FGS may de-
velop in childhood, it is surprising that with the prevalence of S. hae-
matobium estimated at up to 25% in a survey of school-age children in a
majority of sub-Saharan African countries (Lai et al., 2015), less than
half of the countries (shaded red in Figure 1C) have formally published
FGS case estimates. No population prevalence studies have been per-
formed but best estimates are that 20 - 56 million women in sub-Sa-
haran Africa may be living with FGS (World Health Organization 2017).
3.3. FGS morbidity and clinical presentation
Studies of FGS histopathology reported that women ultimately di-
agnosed with FGS initially sought care for vaginal bleeding, abdominal
pain, or infertility (Swai et al., 2006). Frequently associated, but not
Figure 2. The anatomy of female genital and female urogenital schistosomiasis.
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pathognomonic, symptoms included haematuria, dyspareunia, and
post-coital bleeding (Kjetland et al., 1996). FGS has characteristic
clinical findings: grainy sandy patches (representing ova near the mu-
cosal surface) (Kjetland et al., 1996), homogenous yellow sandy patches
(Kjetland et al., 2005), and rubbery papules (Figure 3). These lesions
are associated with neovascularization (Kjetland et al., 1996; Kjetland
et al., 2005) and contact bleeding (Kjetland et al., 1996; Kjetland et al.,
2005). Common sites for egg visualization in adult females were the
cervix (Kjetland et al., 2005), vagina (Kjetland et al., 2005), and vulva
(Kjetland et al., 1996) while women under the age of 20 commonly
presented with vulvar lesions (Helling-Giese et al., 1996; Swai et al.,
2006). The difference in presentation may be related to anatomic,
hormonal, and vascular changes associated with puberty (Helling-
Giese et al., 1996).
3.4. Treatment of S. haematobium infection and FGS with praziquantel
Currently the World Health Organization (WHO) recommends pra-
ziquantel (PZQ) mass drug administration (MDA) to control S. haema-
tobium disease and reduce morbidity. Data on the effect of PZQ on FGS
lesion reversibility are scarce and subject to limitations. To date, three
studies of adult women with FGS followed after treatment with PZQ
have been conducted in Zimbabwe (n=338), Tanzania (n=33), and
Malawi (n=9). All three suggested that, following treatment with at
least 40mg/kg of PZQ, a proportion of cervicovaginal lesions are irre-
versible with variation by lesion type, duration of follow-up, and pra-
ziquantel dose provided (Richter et al., 1996; Kjetland et al., 2006;
Downs et al., 2013). Data from Zimbabwe suggested that women
treated for schistosomiasis prior to the age of 20 had significantly lower
prevalence of sandy patches and contact bleeding than untreated
women (Kjetland et al., 2008). PZQ administration prior to the age of
21 has also been associated with lower rates of sub-fertility (Miller-
Fellows et al., 2017). Thus, it is critical that schistosomiasis treatment
occurs early, prior to the development of FGS lesions. Further well-
designed clinical trials are required to investigate this question.
In addition to its role in schistosomiasis morbidity reduction,
mathematical modelling suggests that PZQ treatment of women and
school-aged children in S. haematobium high-risk communities could
reduce HIV-1 prevalence (Gibson et al., 2010; Mushayabasa and Bhunu
2011; Ndeffo Mbah et al., 2013; Ndeffo Mbah et al., 2014). This finding
highlights the need for further research into the use of PZQ for HIV-1
prevention. Other effective HIV-1 prevention methods include anti-
retroviral therapy and pre-exposure prophylaxis (PrEP). However, even
with the use of linkage strategies, PrEP (Mugwanya, 2018) and ART
uptake (Bor et al., 2018) and coverage are substantially less than 100%
(Granich et al., 2015), and PrEP adherence in both men and women is
imperfect (Koss et al., 2017). These limitations outline the need for a
comprehensive approach to HIV-1 prevention, and further research is
needed to evaluate praziquantel's role.
3.5. The impact of FGS on reproductive health
Due to its ability to affect both the upper and lower female re-
productive tract, FGS has been implicated in poor reproductive health
outcomes. However, data are mostly limited to pathology and case re-
ports. Pathology reports described the presence of severe scarring
(Swai et al., 2006) and inflammation (Wright et al., 1982; Swai et al.,
2006) in the fallopian tubes related to the presence of S. haematobium
eggs. Case reports described poor pregnancy outcomes in FGS, in-
cluding stillbirth (Helling-Giese et al., 1996), ectopic pregnancy
(Helling-Giese et al., 1996; Odubamowo et al., 2014) and spontaneous
abortion (Helling-Giese et al., 1996; Friedman et al., 2007). The ne-
gative impact of FGS on reproductive health is most likely mediated
through the histologic and mechanical effect of tissue destruction
caused by schistosome eggs (Kjetland et al., 2010), but more research is
urgently needed to understand the detrimental implications of FGS for a
woman's sexual and reproductive health. Additional adverse outcomes
attributed to S. haematobium infection in pregnancy include anemia,
preterm labor, intrauterine growth restriction, and low birth weight
(Friedman et al., 2007).
Infertility, a known consequence of upper reproductive tract pa-
thology, is another reproductive health outcome that is associated with
S. haematobium (Woodall and Kramer 2018). A 44% prevalence of sub-
fertility (higher than worldwide averages of 8-12%) has been reported
in women living in an area of high S. haematobium endemicity (60-85%
prevalence in school-age children) (Miller-Fellows et al., 2017). FGS,
defined in this study as the finding of S. haematobium ova in Papani-
colau smears, was associated with primary infertility, defined as the
inability to conceive after four years of regular sexual activity (OR 3.6;
1.0 – 12.0, p=0.04) (Kjetland et al., 2010). The distribution of sec-
ondary infertility (infertility after giving birth to a child) overlaps
substantially with the distribution of FGS in sub-Saharan Africa
(Figure 1A and 1D).
4. Female Genital Schistosomiasis and HIV-1 co-infection
4.1. S. haematobium and HIV-1 – epidemiology and an ecological
association
In addition to biologic plausibility supporting the association be-
tween an entity that causes cervicovaginal barrier disruption and HIV-1
acquisition, ecological associations have been reported between S.
haematobium and HIV-1 (Mbah et al., 2013; Brodish and Singh 2016).
The epidemiology of both schistosomiasis and HIV-1 may be influenced
by interactions between the two infections, but individual studies have
reported disparate conclusions regarding egg excretion, infection in-
tensity, and association of schistosome infection with HIV-1. Ten stu-
dies that evaluated the association of non-genital schistosomiasis with
HIV-1 met our inclusion criteria. Four studies with varied methodolo-
gies suggested an association between schistosome infection (genital
Figure 3. Visual findings suggestive of Female Genital Schistosomiasis, from World Health Organization (2015).
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infection status was not reported) and HIV-1 (N'Zoukoudi-
N'Doundou et al., 1995; Ndhlovu et al., 2007; Downs et al., 2012;
Downs et al., 2017) albeit the association in two studies was only seen
within sub-groups (Ndhlovu et al., 2007; Downs et al., 2017). Of note
two of the studies found an association with HIV-1 evaluate S. haema-
tobium (N'Zoukoudi-N'Doundou et al., 1995; Ndhlovu et al., 2007) and
two studies measured CAA (Downs et al., 2012; Downs et al., 2017),
which suggests active schistosome infection but cannot differentiate
between S. haematobium or S. mansoni species. Conversely, six cross-
sectional or case-control studies identified in our search evaluated the
association between schistosome infection and HIV-1 did not show an
association between schistosome and HIV-1 infection (Fontanet et al.,
2000; Kallestrup et al., 2005; Mazigo et al., 2014; Sanya et al., 2015;
Ssetaala et al., 2015; Downs et al., 2017), of note, none of these studies
described FGS or S. haematobium infection in isolation. Meaningful
comparison across studies was limited by variations in diagnostic
methods and definitions of schistosome infection and many studies did
not report analyses stratified by sex. In those that did, associations
between schistosome infection and HIV-1 prevalence (Downs et al.,
2012), increased acquisition (Downs et al., 2017), or transmission
(Wall et al., 2018) were commonly (although not universally) seen in
females but not in males. In females, cervicovaginal schistosome egg-
containing tissue is exposed to semen containing HIV-1. The prostate
and seminal vesicles are commonly affected by S. haematobium in men
(Kayuni et al., 2019), internal structures that are not exposed during
sexual contact. Authors finding a difference in the association between
schistosomiasis and HIV-1 infection by sex hypothesize that this may be
due to differential contact of egg-containing tissues in female versus
male genital tissues during sexual contact (Downs et al., 2017).
4.2. FGS as a risk factor for the heterosexual acquisition of HIV-1
While the majority of studies examine the association between
schistosome infection and HIV-1, our search identified only two studies
that evaluate a definition of FGS that includes egg deposition in genital
tissue, and its association with prevalent HIV-1 (Supplementary
Table 1). Data from these two cross-sectional studies suggested that
women with FGS have increased odds of having HIV-1 (Kjetland et al.,
2006). One study performed in rural Zimbabwe, found that 41% (29/
70) of women with FGS (diagnosed by S. haematobium eggs in Papa-
nicolaou, wet smear, or genital biopsy) were HIV-1 positive, compared
with 26% (96/375) in the egg negative group (OR 2.1, 95% CI 1.2-3.5;
p=0.008) (Kjetland et al., 2006). A study in Tanzania investigated HIV-
1 prevalence among women with FUS (defined as either urinary S.
haematobium egg excretion (16/23 participants) or egg detection in
genital tissue (7/23 participants)), found that of the 23 women with
FUS, 4 (17.4%) were HIV-1 infected compared with 23 (5.3%) of 434
women without FUS (OR 4.0, 95% CI 1.2–13.5) (Downs et al., 2011).
This study was limited by small numbers, a low number of women with
eggs detected in genital tissue, and the use of a broad FUS definition.
4.3. Schistosomiasis as a risk factor for HIV-1 incidence and transmission
To our knowledge, published data evaluating the association of FGS
with HIV-1 incidence or transmission are lacking, although a small
number of studies have evaluated the association of schistosome in-
fection with HIV-1 (but genital infection status was not reported in
these studies) (Downs et al., 2017; Wall et al., 2018). A retrospective
analysis of a longitudinal cohort study of HIV-1 incidence in anti-ret-
roviral therapy (ART) naïve, heterosexual HIV-1 serodiscordant couples
in Zambia examined the association of baseline schistosome antibody
status (as a proxy for previous or current infection) with incident HIV-1
acquisition and transmission (Wall et al., 2018). The presence of S.
haematobium antibodies in 482 HIV-1 negative women was associated
with increased risk of HIV-1 acquisition (Wall et al., 2018). However,
limitations include the absence of information on the timing of the
index partner's HIV-1 infection, the use of Schistosoma serology, which
does not differentiate between past or present infection, and missing
data on ART initiation. Research is needed to evaluate the association of
FGS with HIV-1 incidence and transmission in the era of universal ART.
4.4. The intersection of FGS and host HIV-1 susceptibility
S. haematobium egg deposition in the female reproductive tract leads
to a histological microenvironment that may enhance HIV-1 vulner-
ability. HIV-1 susceptibility is influenced by multiple factors but ulti-
mately requires the presence of susceptible host cells (commonly in the
vagina or cervix) (Kaul et al., 2015). HIV-1 fusion with and entry into
susceptible target cells (T-lymphocytes, monocyte/macrophages or
dendritic/Langerhans cells) requires the expression of the principal CD4
receptor and a chemokine co-receptor (CCR5 or CXCR4) (Kaul et al.,
2015). These target cells and their chemokine co-receptors are found in
the human genital tract (Kaul et al., 2015). HIV-1 susceptibility in the
host is influenced by the overall number (Secor et al., 2003), density,
and expression of the chemokine co-receptors on target cells that can be
utilized by HIV-1 for cellular entry (Kaul et al., 2015). Certain CD4+
subsets are more susceptible to HIV-1 infection (McKinnon et al., 2011)
and thus the availability, activation status, and phenotype of mucosal
target cells influence HIV-1 susceptibility (Secor et al., 2003;
McKinnon and Kaul 2012). In women with FGS, cervical tissue con-
taining S. haematobium eggs has an increased density of CD4+ lym-
phocytes and macrophages compared to cervical tissue not containing
eggs (Jourdan et al., 2011). On a histological level, cervical tissue
containing S. haematobium eggs is also more vascularized (Jourdan
et al., 2011) potentially allowing increased vascular access to HIV-1
target cells. Thus, the granuloma environment in S. haematobium in-
fection theoretically encourages a milieu of cellular populations ne-
cessary to establish HIV-1 infection.
Compared to egg negative men, egg-positive S. mansoni infection in
Kenyan males was associated with a higher density of CCR5 and CXCR4
co-receptors in the peripheral blood (Secor et al., 2003). Such data are
not available in S. haematobium infection and are hypothesis-generating
regarding the association between schistosome infection and HIV-1
status. Limited data exist regarding the influence of FGS on co-receptor
expression. A small study conducted in KwaZulu-Natal, South Africa
followed 14 women aged 15 – 23 years with FGS (defined by a sug-
gestive clinical exam) for 8 months (Kleppa et al., 2014). Flow-cyto-
metry was performed from peripheral blood and cervical cytobrush
samples before and after praziquantel treatment. Compared to FGS
negative women, participants with FGS had increased expression of the
CCR5 co-receptor on plasma CD4 cells and vaginal CD14+ monocytes
and increased frequencies of systemic monocytes (Kleppa et al., 2014).
Increased frequencies of HIV-1 target cells and co-receptor expression
are plausible mechanisms for increased HIV-1 vulnerability in women
with FGS, but given the small sample size and the lack of histologic or
laboratory diagnosis of FGS, additional research is needed.
5. Does FGS behave like an STI or bacterial vaginosis in
heterosexual HIV-1 acquisition? Mechanistic hypotheses for the
role of FGS in HIV-1 vulnerability
Although the association between FGS and HIV-1 has been hy-
pothesized to be a direct result of FGS-associated lesions in the female
genital tract (Feldmeier et al., 1994; Kjetland et al., 2005), the me-
chanism of the HIV-1 vulnerability has not been fully described. In
ulcerative STIs (e.g. syphilis or herpes simplex virus (HSV)), damage to
the protective cervicovaginal barrier is associated with increased risk of
HIV-1 transmission (Gray et al., 2001) and acquisition (McKinnon and
Kaul 2012). In this section we put forth several hypotheses (Figure 4)
for how FGS may influence mechanisms associated with HIV-1 acqui-
sition. In addition to causing barrier dysfunction, STIs, and perhaps also
FGS, increase the risk of HIV-1 transmission through their contribution
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to genital HIV-1 replication (Cohen et al., 1997) and HIV-1 acquisition
through genital inflammation (Masson et al., 2014; Masson et al., 2015)
and HIV-1 target cell recruitment (Masson et al., 2014).
5.1. Impaired cervicovaginal barrier function
In the female genital tract, the cervicovaginal immune defences are
physical and immunological (Selhorst et al., 2017). An intact vaginal
mucus layer, antimicrobial peptides, an acidic pH, and optimal vaginal
microbiota combined with a preserved cervicovaginal epithelium pro-
vide an effective barrier, the first defence against HIV-1 acquisition
(Selhorst et al., 2017). STIs are a classic example of how compromised
cervicovaginal barriers increase susceptibility to HIV-1 acquisition. Like
STIs, the characteristic lesions of FGS represent a breach in the intact
cervicovaginal mucosal barrier and are hypothesized to be an entry
point for HIV-1 (Feldmeier et al., 1995). At a population level, non-
ulcerative STIs may be more important given their higher incidence and
prevalence. And unlike many bacterial STIs which resolve with ap-
propriate treatment, a proportion of FGS genital lesions may persist
despite treatment with praziquantel (see section 3.4) (Downs et al.,
2013). Further research is needed to evaluate if, similar to HSV ulcers,
healed FGS lesions are associated with persistent localized inflamma-
tion, including HIV-1 target cells (Zhu et al., 2009).
5.2. The role of vaginal inflammation in HIV-1 acquisition. Could FGS
contribute?
Inflammation and immune activation are central to HIV-1 patho-
genesis and acquisition. Biological mechanisms that are influenced by
vaginal inflammation and contribute to male-to-female heterosexual
HIV-1 acquisition include mucosal target cell recruitment
(McKinnon and Kaul 2012) and impaired cervicovaginal barrier func-
tion (Arnold et al., 2016). Initiation of the inflammatory cascade
functions to recruit immunologic cellular mediators. In an escalating
onward cascade, the presence of vaginal inflammation recruits the very
cells needed to establish HIV-1 infection (Arnold et al., 2016). HIV-1
can infect T-lymphocytes, macrophages, and dendritic cells present in
the cervicovaginal tissue (McKinnon and Kaul 2012). Elevated genital
cytokines affect the expression of proteins associated with the cervi-
covaginal epithelium's integrity (Arnold et al., 2016). Compromise of
this physical barrier occurs in FGS and provides a rich supply of acti-
vated and available subepithelial HIV-1 target cells.
S. haematobium infection has been associated with altered levels of
systemic (Lyke et al., 2006; Erikstrup et al., 2008), seminal fluid
(Leutscher et al., 2005), and vaginal cytokines (Dupnik et al., 2018).
Raised vaginal concentrations of chemotactic (Morrison et al., 2014)
and inflammatory cytokines are a risk factor for HIV-1 acquisition
(Masson et al., 2015). In a study of 58 female HIV-1 seroconverters in
South Africa, women with elevation of more than 5 out of 9 in-
flammatory cytokines had increased odds of HIV-1 acquisition (OR 3.2,
95% CI 1.3-7.9) (Masson et al., 2015). Mechanistically, the association
has biological plausibility, as the production of inflammatory cytokines
can influence expression of biomarkers of tissue remodelling and in-
tegrity (Arnold et al., 2016), modulate HIV-1 replication through
transcription factor expression (Masson et al., 2014), or indirectly in-
fluence the differentiation, proliferation, and activation of HIV-1 target
cells (Masson et al., 2014). Further research is needed to evaluate if FGS
is associated with the genital inflammatory cytokines that are also as-
sociated with HIV-1 infection (Masson et al., 2015).
5.3. HIV-1 RNA concentrations, schistosomiasis, and HIV-1 transmission
Treatment of bacterial STI with antibiotics significantly decreases
the concentration of HIV-1 RNA in seminal plasma (Cohen et al., 1997).
Similarly, African men with genital schistosomiasis showed a decline in
the concentration of HIV-1 RNA in seminal plasma after treatment with
praziquantel (Midzi et al., 2017). Immunologically, egg-positive schis-
tosome infection induces a strong Th2 bias (Pearce et al., 1991). Lim-
ited data suggest that HIV-1 replicates preferentially in activated CD4
Th0/Th2 cells (Maggi et al., 1994). Thus, there is immunologic plau-
sibility to a hypothesis linking schistosomiasis with HIV-1 transmission.
Practically, this may manifest as altered plasma and genital HIV-1 RNA
concentrations among those who are dually infected with HIV-1 and
schistosomiasis. Understanding the effect of schistosome infection on
HIV-1 viral loads is critical given that schistosome infection in both
women and men has been associated with HIV-1 transmission
(Wall et al., 2018). However, the data regarding the association of
schistosomiasis with elevated plasma viral loads are conflicting (Downs
et al., 2017; Colombe et al., 2018; Bochner et al., 2019) and there may
be a species-specific effect of Schistosoma on viral load (Bochner et al.,
2019). In a study of HIV-1 seroconversion, participants with S. hae-
matobium had higher set point plasma viral loads (+0.33 log10 copies,
95%CI -0.07-0.73, p=0.11) compared to uninfected individuals, while
participants with S. mansoni had lower set point HIV-1 viral loads (-0.34
log10 copies, 95% CI -0.58 to -0.09,p=0.007) (Bochner et al., 2019).
Recent longitudinal studies report both increased (Downs et al., 2017)
and decreased (Colombe et al., 2018; Bochner et al., 2019) HIV-1 viral
load set points in participants co-infected with HIV-1 and S. mansoni. Of
note, FGS status was not evaluated in these studies (Downs et al., 2017;
Colombe et al., 2018; Bochner et al., 2019). Differences in the results
Figure 4. Conceptual pathway describing the potential contribution of FGS to vaginal inflammation and the association of FGS with sexually transmitted infection
and “non-optimal” cervicovaginal microbiota (McKinnon et al., 2019).
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highlight the need to adjust for ART use and duration of HIV-1 infection
when evaluating HIV-1 viral load in the context of schistosomiasis
(Downs et al., 2017; Colombe et al., 2018; Bochner et al., 2019).
An elevated genital HIV-1 viral load is a known risk factor for HIV-1
transmission (Baeten et al., 2011). An analysis of four prospective co-
hort studies in HIV negative persons in Kenya or Uganda who experi-
enced HIV-1 seroconversion provided data regarding the association of
schistosome infection with altered genital HIV-1 RNA concentrations.
After adjusting for age, year of HIV-1 acquisition, and log10 plasma viral
load, 8 women with S. haematobium infection who acquired HIV-1 were
found to have lower cervical (ß=-0.59 [-1.11- -0.06], p=0.029) and
similar vaginal (ß =-0.09 (-0.65-0.46), p=0.74) HIV-1 viral loads
compared with participants who did not have schistosomiasis
(Bochner et al., 2019). However, since the numbers were small, the
estimates were not adjusted for multiple comparisons, and genital
schistosomiasis status was not assessed, further research is needed to
describe the association of FGS with genital HIV-1 RNA concentrations.
5.4. Vaginal microbiota in S. haematobium endemic countries and the risk
of HIV-1 acquisition
Optimal vaginal microbiota are characterized by the presence of
lactic acid and hydrogen-peroxide producing bacteria, often
Lactobacilli. “Non-optimal” cervicovaginal microbiota (McKinnon et al.,
2019) is not dominated by Lactobacilli. Bacterial vaginosis (BV) is one
condition within this category (Cohen et al., 2012). BV involves the
replacement of lactic acid producing bacteria by anaerobes, with bac-
terial species often clustering into distinct communities
(McKinnon et al., 2019). Prevalence of BV is estimated to be high
among women in sub-Saharan Africa (Cohen et al., 2012) and women
of African descent. Although BV is seldom associated with clinically
visible inflammation (McKinnon et al., 2019), it is consistently asso-
ciated with elevated concentrations of pro-inflammatory immune pro-
teins (Masson et al., 2014) and poor sexual and reproductive health
outcomes, such as preterm delivery, miscarriage, pelvic inflammatory
disease, and HIV-1 acquisition (Atashili et al., 2008). A meta-analysis of
HIV-1 incidence studies reported that the presence of BV resulted in a
60% increased risk of HIV-1 acquisition (Atashili et al., 2008). Potential
factors contributing to this increased risk include an increase in vaginal
pH and upregulation of cytokines that promote HIV-1 replication
(Masson et al., 2014). As a chronic and recurrent disruption of the
genital tract environment, BV contributes a substantial population at-
tributable fraction (PAF) of HIV-1 acquisition (Masese et al., 2015).
Given the substantial risk for HIV-1 acquisition that BV poses in sub-
Saharan Africa, it is critical to evaluate if FGS might also be associated
with changes in the cervicovaginal microbiota. Since the cervicovaginal
presence of FGS likely persists over time, FGS may, like BV, contribute a
high PAF for HIV-1 acquisition.
Research on the role of the gut microbiota in persons with urinary S.
haematobium suggested that the effect of urinary S. haematobium in-
fection may be manifest in body compartments distinct from the loca-
tion of egg deposition (Kay et al., 2015). The differential detection of
microbes based on Schistosoma infection status extended into the ur-
inary microbiota as well (Adebayo et al., 2017). That S. haematobium
infection is associated with alteration in the gut and urinary microbiota
lends plausibility to the hypothesis that FGS may alter the cervi-
covaginal microbiota. The composition of the vaginal microbiota
played a role in HIV-1 acquisition, as demonstrated by a study of 236
South African women, 31 of whom acquired HIV-1 after a median 335
days of follow-up. This study illustrated that compared with Lactoba-
cillus crispatus dominance, high-diversity vaginal bacterial communities
with low Lactobacillus abundance was associated with HIV-1 acquisition
(Gosmann et al., 2017), however FGS or schistosome infection was not
evaluated. Women with anaerobic dominance were also found to have
increased genital CD4+ T-cell numbers, concentrations of cytokines
produced by activated CD4+ cells (Gosmann et al., 2017), and
cytokines that have been associated with HIV-1 acquisition
(Masson et al., 2015). Further research is needed to evaluate the po-
tential mechanistic connection between the vaginal microbiota and
FGS.
6. Female Genital Schistosomiasis – research priorities
This review highlights gaps in the literature and the need for revised
research priorities that evaluate the mechanistic links between FGS and
HIV-1 acquisition and transmission. Research regarding additional
biological mechanisms for HIV-1 vulnerability in FGS is urgently
needed and future research must explore the association of FGS with: 1)
cervicovaginal HIV-1 concentrations 2) cytokines and chemokines as-
sociated with HIV-1 acquisition, and 3) vaginal microbial community
composition.
7. Conclusion
FGS is a neglected gynaecological disease of poverty, affecting
vulnerable women in sub-Saharan Africa. FGS may be an unmeasured
regional risk factor that compounds biological and cultural covariates
in a population at risk for HIV-1 acquisition and transmission. The
clinical cervicovaginal findings of FGS demonstrate a breach in the
physical epithelial barrier. This mechanical mucosal defect may allow
greater access to the HIV-1 target cells in the sub-mucosa. However, the
hypothesis that cervicovaginal barrier dysfunction in FGS is the sole
mechanism linking FGS and HIV-1 acquisition is likely incomplete. The
experience of STI and BV and their association with HIV-1 vulnerability
includes consideration of additional co-factors: target cell recruitment,
vaginal inflammation, and HIV-1 RNA concentrations. A more complete
understanding of the association of FGS with HIV-1 will advance the
research agenda on diagnostic, therapeutic and prevention strategies
for this disabling disease, and its synergistic role in the HIV-1 epidemic.
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